chen, chenyan – page 6 – eisai china lnc.-开元体育官网下载手机版

 chen, chenyan – page 6 – eisai china lnc.-开元体育官网下载手机版

entries by

launch meeting of the third-generation antiepileptic drug of fycompa (perampanel) in china

eisai china inc. (hereinafter referred to as “eisai china”) successfully held the launch meeting of fycompa® (perampanel) in china on december 1, 2019, which marks the official launch of the new third-generation antiepileptic drug of fycompa® in china. this means that the first non-competitive ampa receptor antagonist is officially ushered in the field of epilepsy treatment in china, which will bring new treatment methods and means for the majority of patients with epilepsy and their families.

mr. yamada koki, deputy general manager of eisai (china) pharmaceutical co., ltd. (hereinafter referred to as “eisai china”), attended the 2018-2019 annual awards ceremony for advanced collectives and outstanding individuals in peking university health science center, on behalf of eisai china, on november 26, 2019. a total of 40 students won the eisai china scholarships for their outstanding performance, and 10 students got the eisai china grants during this academic year. eisai china has awarded scholarships and grants to outstanding students at peking university health science center for 8 consecutive years.

eisai china successfully held “2019 ads beijing “

on october 19, 2019, the “2019 ads beijing” sponsored by eisai china inc. was held in beijing, which is another platform for doctors’ information exchanges. featuring the theme of “let’s build hope together”, the main forum and three sub-forums focused on the latest cutting-edge academic research and clinical practice and development in china and in the world. 37 well-known experts and scholars from china, japan, singapore, spain and other countries, more than 300 on-site guests and nearly 1,000 on-line guests jointly discussed and conducted dialogues and interactions, producing collision of ideas and academic resonance between china and foreign countries. 

new drug approval for fycompa® for adjunctive treatment of partial onset seizures in china

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today thateisai received a new drug approval for its in-house discovered and developed antiepileptic drug (aed) fycompa® (perampanel) from the china national medical products administration (nmpa) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures)in epilepsy patients 12 years of age and older. fycompa was designated for priority review by the nmpa due to itssignificant clinical benefits compared to existing treatments, and was approved in about 12 months since the submission in september 2018.

eisai and fronteo to launch coroban® tumbling and falling prediction system for inpatients

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and fronteo, inc. (headquarters: tokyo, ceo: masahiro morimoto, “fronteo”) announced today that they have launched the tumbling and falling prediction system coroban® to medical institutions in japan on september 26, 2019. the coroban  predicts inpatients’ tumbling and falling risks in advance and displays alerts.